A Novel Circulating MicroRNA for the Detection of Acute Myocarditis.

BACKGROUND The diagnosis of acute myocarditis typically requires either endomyocardial biopsy (which is invasive) or cardiovascular magnetic resonance imaging (which is not universally available). Additional approaches to diagnosis are desirable. We sought to identify a novel microRNA for the diagnosis of acute myocarditis. METHODS To identify a microRNA specific for myocarditis, we performed microRNA microarray analyses and quantitative polymerase-chain-reaction (qPCR) assays in sorted CD4+ T cells and type 17 helper T (Th17) cells after inducing experimental autoimmune myocarditis or myocardial infarction in mice. We also performed qPCR in samples from coxsackievirus-induced myocarditis in mice. We then identified the human homologue for this microRNA and compared its expression in plasma obtained from patients with acute myocarditis with the expression in various controls. RESULTS We confirmed that Th17 cells, which are characterized by the production of interleukin-17, are a characteristic feature of myocardial injury in the acute phase of myocarditis. The microRNA mmu-miR-721 was synthesized by Th17 cells and was present in the plasma of mice with acute autoimmune or viral myocarditis but not in those with acute myocardial infarction. The human homologue, designated hsa-miR-Chr8:96, was identified in four independent cohorts of patients with myocarditis. The area under the receiver-operating-characteristic curve for this novel microRNA for distinguishing patients with acute myocarditis from those with myocardial infarction was 0.927 (95% confidence interval, 0.879 to 0.975). The microRNA retained its diagnostic value in models after adjustment for age, sex, ejection fraction, and serum troponin level. CONCLUSIONS After identifying a novel microRNA in mice and humans with myocarditis, we found that the human homologue (hsa-miR-Chr8:96) could be used to distinguish patients with myocarditis from those with myocardial infarction. (Funded by the Spanish Ministry of Science and Innovation and others.).

[1]  H. Schultheiss,et al.  MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies , 2020, ESC heart failure.

[2]  Qiming Liu,et al.  Expression of serum microRNA-155 and its clinical importance in patients with heart failure after myocardial infarction , 2019, The Journal of international medical research.

[3]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[4]  C. Grines,et al.  State of the art: Evaluation and prognostication of myocarditis using cardiac MRI , 2019, Journal of magnetic resonance imaging : JMRI.

[5]  N. Sato Call for action to establish standard diagnostic and therapeutic approaches for myocarditis. , 2019, International journal of cardiology.

[6]  H. Jneid,et al.  Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association , 2019, Circulation.

[7]  S. Iliceto,et al.  How to improve therapy in myocarditis: role of cardiovascular magnetic resonance and of endomyocardial biopsy , 2019, European heart journal supplements : journal of the European Society of Cardiology.

[8]  M. Halushka,et al.  Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. , 2019, Annual review of pathology.

[9]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. , 2018, Journal of the American College of Cardiology.

[10]  C. Antoniades,et al.  Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis: A Systematic Review and Meta-Analysis. , 2018, JACC. Cardiovascular imaging.

[11]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[12]  R. Manka,et al.  Approximation of the Incidence of Myocarditis by Systematic Screening With Cardiac Magnetic Resonance Imaging. , 2018, JACC. Heart failure.

[13]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[14]  Xianhui Zhou,et al.  Circulating miRNA‑21 is a promising biomarker for heart failure. , 2017, Molecular medicine reports.

[15]  U. Eriksson,et al.  The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[16]  L. Cooper,et al.  Cardiac myosin-Th17 responses promote heart failure in human myocarditis. , 2016, JCI insight.

[17]  Matthias Gutberlet,et al.  Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. , 2016, Journal of the American College of Cardiology.

[18]  S. Iliceto,et al.  Clinical presentation and diagnosis of myocarditis , 2015, Heart.

[19]  S. Dimmeler,et al.  MicroRNAs in myocardial infarction , 2015, Nature Reviews Cardiology.

[20]  J. Kaski,et al.  Proteasome-Mediated Reduction in Proapoptotic Molecule Bim Renders CD4+CD28null T Cells Resistant to Apoptosis in Acute Coronary Syndrome , 2015, Circulation.

[21]  L. Tao,et al.  MicroRNA‑21 regulation of the progression of viral myocarditis to dilated cardiomyopathy. , 2014, Molecular medicine reports.

[22]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[23]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[24]  Soyoung Lee,et al.  Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17–producing T-helper cell differentiation , 2013, Proceedings of the National Academy of Sciences.

[25]  S. Huber,et al.  Autoimmune Myocarditis, Valvulitis, and Cardiomyopathy , 2013, Current protocols in immunology.

[26]  N. Danchin,et al.  Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. , 2013, European heart journal.

[27]  Stephane Heymans,et al.  MicroRNA Profiling Identifies MicroRNA-155 as an Adverse Mediator of Cardiac Injury and Dysfunction During Acute Viral Myocarditis , 2012, Circulation research.

[28]  Pilar Martín,et al.  CD69 Limits the Severity of Cardiomyopathy After Autoimmune Myocarditis , 2010, Circulation.

[29]  Ryan M. O’Connell,et al.  MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. , 2010, Immunity.

[30]  Y. Liao,et al.  Th17 Cells Facilitate the Humoral Immune Response in Patients with Acute Viral Myocarditis , 2010, Journal of Clinical Immunology.

[31]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[32]  N. Rose,et al.  Pathogenesis of myocarditis and dilated cardiomyopathy. , 2008, Advances in immunology.

[33]  M. Kurrer,et al.  T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17 , 2006, The Journal of experimental medicine.

[34]  T. Dalmay,et al.  Identification of new central nervous system specific mouse microRNAs , 2006, FEBS letters.

[35]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.